Biomarkers in chronic graft-versus-host disease

Expert Review of Hematology

Volumn 4, Issue 3, 2011, Pages 329-342

  Rozmus, Jacob ^a   Schultz, Kirk R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

allogeneic hematopoietic stem cell transplantation; biomarkers; chronic graft versus host disease; graft versus leukemia

Indexed keywords

BIOLOGICAL MARKER;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; DIAGNOSTIC VALUE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOPATHOGENESIS; MORBIDITY; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE;

BIOLOGICAL MARKERS; CHRONIC DISEASE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA ANTIGENS; HUMANS; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 79959257982     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/ehm.11.27     Document Type: Review

References (155)

1. Gaziev J, Sodani P, Lucarelli G. Hematopoietic stem cell transplantation in thalassemia. Bone Marrow Transplant. 42(Suppl. 1), S41 (2008)
2. Filipovich A. Hematopoietic cell transplantation for correction of primary immunodeficiencies. Bone Marrow Transplant. 42(Suppl. 1), S49-S52 (2008)
3. Mehta P, Locatelli F, Stary J, Smith FO. Bone marrow transplantation for inherited bone marrow failure syndromes. Pediatr. Clin. North Am. 57(1), 147-170 (2010)
4. Prasad VK, Kurtzberg J. Cord blood and bone marrow transplantation in inherited metabolic diseases: scientific basis, current status and future directions. Br. J. Haematol. 148(3), 356-372 (2010)
5. Sullivan KM, Muraro P, Tyndall A. Hematopoietic cell transplantation for autoimmune disease: updates from Europe and the United States. Biol. Blood Marrow Transplant. 16(Suppl. 1), S48-S56 (2010)
6. Filipovich AH, Weisdorf D, Pavletic S et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic-graft-versus-host disease: I. Diagnosis and staging working group report. Biol. Blood Marrow Transplant. 11(12), 945-956 (2005)
7. Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 95(9), 2754-2759 (2000)
8. Gooley TA, Chien JW, Pergam SA et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N. Engl. J. Med. 363(22), 2091-2101 (2010)
9. Fraser C, Bhatia S, Ness K et al. Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant. Survivor Study. Blood 108(8), 2867-2873 (2006)
10. Lee SJ. Have me made progress in the management of chronic graft-vs-host disease? Best Pract. Res. Clin. Haematol. 23(4), 529-535 (2010)
11. Arora M, Burns LJ, Davies SM et al. Chronic graft-versus-host disease: a prospective cohort study. Biol. Blood Marrow Transplant. 9(1), 38-45 (2003)
12. Bhatia S, Francisco L, Carter A et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood 110(10), 3784-3792 (2007)
13. Weiden PL, Flournoy N, Thomas ED et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N. Engl. J. Med. 300(19), 1068-1073 (1979)
14. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N. Engl. J. Med. 304(25), 1529-1533 (1981)
15. Ringdén O, Karlsson H, Olsson R, Omazic B, Uhlin M. The allogeneic graft-versus-cancer effect. Br. J. Haematol. 147(5), 614-633 (2009)
16. Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 112(12), 4371-4383 (2008)
17. Olkinuora H, von Willebrand E, Kantele JM et al. The impact of early viral infections and graft-versus-host disease on immune reconstitution following pediatric stem cell transplantation. Scand. J. Immunol. 14(2), 242-248 (2011)
18. Cuthbert RJ, Iqbal A, Gates A, Toghill PJ, Russell NH. Functional hyposplenism following allogeneic bone marrow transplantation. J. Clin. Pathol. 48(3), 257-259 (1995)
19. Roquette-Gally AM, Boyeldieu D, Prost AC, Gluckman E. Autoimmunity after allogeneic bone marrow transplantation: a study of 53 long-term-surviving patients. Transplantation 46(2), 238-240 (1988)
20. Sherer Y, Shoenfeld Y. Autoimmune diseases and autoimmunity post-bone marrow transplantation. Bone Marrow Transplant. 22(9), 873-881 (1998)
21. Ruoquette-Gally AM, Boyeldieu D, Gluckman E, Abuaf N, Combrisson A. Autoimmunity in 28 patients after allogeneic bone marrow transplantation: comparison with Sjogren s syndrome and scleroderma. Br. J. Haematol. 66(1), 45-47 (1987)
22. Lee, SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol. Blood Transplant. 9(4), 215-233 (2003)
23. Akpek G, Lee SM, Anders V, Vogelsang GB. A high-dose pulse steroid regimen for controlling active chronic graft-versus-host disease. Biol. Blood Marrow Transplant. 7(9), 495-502 (2001)
24. Arora M, Wagner JE, Davies SM et al. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. Biol. Blood Marrow Transplant. 7(5), 265-273 (2001)
25. Ratanatharathorn V, Ayash L, Reynolds C et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol. Blood Marrow Transplant. 9(8), 505-511 (2003)
26. Cutler C, Miklos D, Kim HT et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 108(2), 756-762 (2006)
27. Zaja F, Bacigalupo A, Patriarca F et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant. 40(3), 273-277 (2007)
28. Von Bonin M, Oelschlägel U, Radke J et al. Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab. Transplantation 86(6), 875-879 (2008)
29. Johnston LJ, Brown J, Shizuru JA et al. Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. Biol. Blood Marrow Transplant. 11(1), 47-55 (2005)
30. Martin PJ, Storer BE, Rowley SD et al. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood 113(21), 5074-5082 (2009)
31. Gilman AL, Chan KW, Mogul A et al. Hydroxychloroquine for the treatment of chronic graft-versus-host disease. Biol. Blood Marrow Transplant. 6(3A), 327-334 (2000)
32. Bolaños-Meade J, Jacobsohn D, Anders V et al. Pentostatin in steroid-refractory chronic graft-versus-host disease. Blood 106(11), 513A-514A (2005)
33. Couriel DR, Hosing C, Saliba R et al. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood 107(8), 3074-3080 (2006)
34. Soiffer RJ. Immune modulation and chronic graft-versus-host disease. Bone Marrow Transplant. 42(Suppl. 1), S66-S69 (2008)
35. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69(3), 89-95 (2001)
36. Schultz KR, Miklos DB, Fowler D et al. Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report. Biol. Blood Marrow Transplant. 12(2), 126-137 (2006)
37. Greinix HT, Fae I, Schneider B et al. Impact of HLA class I high-resolution mismatches on chronic graft-versus-host disease and survival of patients given hematopoietic stem cell grafts from unrelated donors. Bone Marrow Transplant. 35(1), 57-62 (2005)
38. Morishima Y, Sasazuki T, Inoko H et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving amarrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood 99(11), 4200-4206 (2002)
39. Flomenberg N, Baxter-Lowe LA, Confer D et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 104(7), 1923-1930 (2004)
40. Teshima T, Matsuo K, Matsue K et al. Impact of human leucocyte antigen mismatch on graft-versus-host disease and graft failure after reduced intensity conditioning allogeneic haematopoietic stem cell transplantation from related donors. Br. J. Haematol. 130(4), 575-587 (2005)
41. Woolfrey A, Klein JP, Haagenson M et al. HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation. Biol. Blood Marrow Transplant. 17(6), 885-892 (2010)
42. Rubinstein P, Carrier C, Scaradavou A et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N. Engl. J. Med. 339(22), 1565-1577 (1998)
43. Gluckman E, Rocha V, Arcese W et al. Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. Exp. Hematol. 32(4), 397-407 (2004)
44. Alsultan A, Giller RH, Gao D et al. GVHD after unrelated cord blood transplant in children: characteristics, severity, risk factors and influence on outcome. Bone Marrow Transplant. 46(5), 668-675 (2011)
45. Herr AL, Kabbara N, Bonfim CM et al. Long-term follow-up and factors influencing outcomes after related HLA-identical cord blood transplantation for patients with malignancies: an analysis on behalf of Eurocord-EBMT. Blood 116(11), 1849-1856 (2010)
46. Arora M, Nagaraj S, Wagner JE et al. Chronic graft-versus-host disease (cGVHD) following unrelated donor hematopoietic stem cell transplantation (HSCT): higher response rate in recipients of unrelated donor (URD) umbilical cord blood (UCB)Biol. Blood Marrow Transplant. 13(10), 1145-1152 (2007)
47. Mutis T, Gillespie G, Schrama E, Falkenburg JH, Moss P, Goulmy E. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease. Nat. Med. 5(7), 839-842 (1999)
48. Loren AW, Bunin GR, Boudreau C et al. Impact of donor and recipient sex and parity on outcomes of HLA-identical sibling allogeneic hematopoietic stem cell transplantation. 12(7), 758-769 (2006)
49. Gahrton G. Risk assessment in haematopoietic stem cell transplantation: impact of donor-recipient sex combination in allogeneic transplantation. Best Pract. Res. Clin. Haematol. 20(2), 219-229 (2007)
50. Spellman S, Warden MB, Haagenson M et al. Effects of mismatching for minor histocompatibility antigens on clinical outcomes in HLA-matched, unrelated hematopoietic stem cell transplants. Biol. Blood Marrow Transplant. 15(7), 856-863 (2009)
51. Ostrovsky O, Shimoni A, Rand A, Vlodavsky I, Nagler A. Genetic variations in the heparanase gene (HPSE) associate with increased risk of GVHD following allogeneic stem cell transplantation: effect of discrepancy between recipients and donors. Blood 115(11), 2319-2328 (2010)
52. Waterman M, Ben-Izhak O, Eliakim R, Groisman G, Vlodavsky I, Ilan N. Heparanase upregulation by colonic epithelium in inflammatory bowel disease. Mod. Pathol. 20(1), 8-14 (2007)
53. Li RW, Freeman C, Yu D et al. Dramatic regulation of heparanase expression in synovium from patients with rheumatoid arthritis. Arthritis Rheum. 58(6), 1590-1600 (2008)
54. Arora M, Lindgren B, Basu S et al. Polymorphisms in the base excision repair pathway and graft-versus-host disease. Leukemia 24(8), 1470-1475 (2010)
55. Ambruzova Z, Mrazek F, Raida L et al. Possible impact of MADCAM1 gene single nucleotide polymorphisms to the outcome of allogeneic hematopoietic stem cell transplantation. Hum. Immunol. 70(6), 457-460 (2009)
56. McGuirk J, Hao G, Hou W et al. Serum proteomic profiling and haptoglobin polymorphisms in patients with GVHD after allogeneic hematopoietic cell transplantation. J. Hematol. Oncol. 2, 17 (2009)
57. Arredouani M, Matthijs P, Van Hoeyveld E et al. Haptoglobin directly affects T cells and suppresses T helper cell type 2 cytokine release. Immunology 108(2), 144-151 (2003)
58. Pagano M, Nicola MA, Engler R. Inhibition of cathepsin L and B by haptoglobin, the haptoglobin-hemoglobin complex, and asialohaptoglobin. In vitro studies in the rat. Can. J. Biochem. 60(6), 631-637 (1982)
59. Sadrzadeh SM, Bozorgmehr J. Haptoglobin phenotypes in health and disorders. Am. J. Clin. Pathol. 121(Suppl.), S97-S104 (2004)
60. Shimada M, Onizuka M, Machida S et al. Association of autoimmune disease-related gene polymorphisms with chronic graft-versus-host disease. Br. J. Haematol. 139(3), 458-463 (2007)
61. Kochi Y, Yamada R, Suzuki A et al. A functional variant in FCRL3, encoding Fc receptor-like 3, is associated with rheumatoid arthritis and several autoimmunities. Nat. Genet. 37(5), 478-485 (2005)
62. Kornblit B, Masmas T, Petersen SL et al. Association of HMGB1 polymorphisms with outcome after allogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 16(2), 239-252 (2010)
63. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells trigger inflammation. Nature 418(6894), 191-195 (2002)
64. Dumitriu IE, Baruah P, Valentinis B et al. Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J. Immunol. 174(12), 7506-7515 (2005)
65. Ek M, Popovic K, Harris HE, Nauclér CS, Wahren-Herlenius M. Increased extracellular levels of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in minor salivary glands of patients with Sj gren s syndrome. Arthritis Rheum. 54(7), 2289-2294 (2006)
66. Popovic K, Ek M, Espinosa A et al. Increased expression of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in skin lesions of patients with lupus erythematosus. Arthritis Rheum. 52(11), 3639-3645 (2005)
67. Inamoto Y, Murata M, Katsumi A et al. Donor single nucleotide polymorphism in the CCR9 gene affects the incidence of skin GVHD. Bone Marrow Transplant. 45(2), 363-369 (2010)
68. Sivula J, Turpeinen H, Volin L, Partanen J. Association of IL-10 and IL-10Rb gene polymorphisms with graft-versus-hostdisease after haematopoietic stem cell transplantation from an HLA-identical sibling donor. BMC Immunol. 10, 24 (2009)
69. Kim DH, Lee NY, Sohn SK et al. IL-10 promoter gene polymorphism associated with the occurrence of chronic GVHD and its clinical course during systemic immunosuppressive treatment for chronic GVHD after allogeneic peripheral blood stem cell transplantation. Transplantation 79(11), 1615-1622 (2005)
70. Takahashi H, Furukawa T, Hashimoto S et al. Contribution of TNF-a and IL-10 gene polymorphisms to graft-versus-host disease following allo-hematopoietic stem cell transplantation. Bone Marrow Transplant. 26(12), 1317-1323 (2000)
71. Bertinetto FE, Dall Omo AM, Mazzola GA et al. Role of non-HLA genetic polymorphisms in graft-versus-host disease after haematopoietic stem cell transplantation. Int. J. Immunogenet. 33(5), 375-384 (2006)
72. Viel DO, Tsuneto LT, Sossai CR et al. IL2 and TNFA gene polymorphisms and the risk of graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. Scand. J. Immunol. 66(6), 703-710 (2007)
73. Laguila Visentainer JE, Lieber SR, Lopes Persoli LB et al. Relationship between cytokine gene polymorphisms and graft-versus-host disease after allogeneic stem cell transplantation in a Brazilian population. Cytokine 32(3-4), 171-177 (2005)
74. Cullup H, Dickinson AM, Cavet J, Jackson GH, Middleton PG. Polymorphisms of interleukin-1a constitute independent risk factors for chronic graft-versus-host disease after allogeneic bone marrow transplantation. Br. J. Haematol. 122(5), 778-787 (2003)
75. Rocha V, Franco RF, Porcher R et al. Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation. Blood 100(12), 3908-3918 (2002)
76. Bogunia-Kubik K, Mlynarczewska A, Wysoczanska B, Lange A. Recipient interferon-g 3/3 genotype contributes to the development of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Haematologica 90(3), 425-426 (2005)
77. Tanaka J, Imamura M, Kasai M et al. Th2 cytokines (IL-4, IL-10 and IL-13) and IL-12 mRNA expression by concanavalin A-stimulated peripheral blood mononuclear cells during chronic graft-versus-host disease. Eur. J. Haematol. 57(1), 111-113 (1996)
78. Skert C, Damiani D, Michelutti A et al. Kinetics of Th1/Th2 cytokines and lymphocyte subsets to predict chronic GVHD after allo-SCT: results of a prospective study. Bone Marrow Transplant. 44(11), 729-737 (2009)
79. Barak V, Levi-Schaffer F, Nisman B, Nagler A. Cytokine dysregulation in chronic graft versus host disease. Leuk. Lymphoma 17(1-2), 169-173 (1995)
80. Ritchie D, Seconi J, Wood C, Walton J, Watt V. Prospective monitoring of tumor necrosis factor a and interferon g to predict the onset of acute and chronic graft-versus-host disease after allogeneic stem cell transplantation. Biol. Blood Marrow Transplant. 11(9), 706-712 (2005)
81. Imamura M, Tsutsumi Y, Miura Y, Toubai T, Tanaka J. Immune reconstitution and tolerance after allogeneic hematopoietic stem cell transplantation. Hematology 8(1), 19-26 (2003)
82. Fimiani M, De Aloe G, Cuccia A. Chronic graft versus host disease and skin. J. Eur. Acad. Dermatol. Venerol. 17(5), 512-517 (2003)
83. Ritchie D, Seconi J, Wood C, Walton J, Watt V. Prospective monitoring of tumor necrosis a and interferon g to predict the onset of acute and chronic graft-versus-host disease after allogeneic stem cell transplantation. Biol. Blood Marrow Transplant. 11(9), 706-712 (2005)
84. Ochs LA, Blazar BR, Roy J, Rest EB, Weisdorf DJ. Cytokine expression in human cutaneous chronic graft-versus-host disease. Bone Marrow Transplant. 17(6), 1085-1092 (1996)
85. Rozmus J, Schultz KR, Wynne K et al. Early and late extensive chronic graft-versus-host disease (cGVHD) in children is characterized by different Th1/Th2 cytokine profiles: findings of the Children s Oncology Group Study (COG), ASCT0031. Biol. Blood Marrow Transplant. (2011) (In Press)
86. +CD25high T cells do not correlate with the establishment of long-term tolerance after allogeneic stem cell transplantation. Exp. Hematol. 33(8), 894-900 (2005)
87. +CD25high regulatory T cells. Blood 103(6), 2410-2416 (2004)
88. Miura Y, Thoburn CJ, Bright EC. Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood 104(7), 2187-2193 (2004)
89. + regulatory T cells and TGF-b at early immune reconstitution is associated to the onset and severity of graft-versus-host disease following allogeneic haematogenesis stem cell transplantation. Leuk. Res. 34(9), 1158-1168 (2010)
90. + regulatory T cells in patients with chronic graft-versus-host disease. Blood 106(8), 2903-2911 (2005)
91. + lymphopenia following allogeneic hematopoietic stem cell transplantation. J. Clin. Invest. 120(5), 1479-1493 (2010)
92. + regulatory T cells in nonlymphopenic hosts. J. Leuk. Biol. 82(5), 1053-1061 (2007)
93. Allan SE, Crome SQ, Crellin NK et al. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int. Immunol. 19(4), 345-354 (2007)
94. Popmihajlov Z, Smith KA. Negative feedback regulation of T cells via interleukin-2 and FOXP3 reciprocity. PLoS One 3(2), e1581 (2008)
95. + effector memory cells relative to central memory cells. Blood 103(10), 3986-3988 (2004)
96. + T cell subsets in chronic graft-versus-host disease. Int. J. Immunopathol. Pharmacol. 22(1), 195-205 (2009)
97. Sato M, Tokuda N, Fukumoto T, Mano T, Sato T, Ueyama Y. Immunohistopathological study of the oral lichenoid lesions of chronic GVHD. J Oral Pathol. Med. 35(1), 33-36 (2006).
98. Dander E, Balduzzi A, Zappa G et al. Interleukin-17-producing T-helper cells as new potential player mediating graft-versus-host disease in patients undergoing allogeneic stem-cell transplantation. Transplantation 88(11), 1261-1272 (2009)
99. Steinman RM, Inaba K. Myeloid dendritic cells. J. Leuk. Biol. 66(2), 205-208 (1999)
100. Waller EK, Rosenthal H, Jones TW et al. Larger numbers of CD4bright dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation. Blood 97(10), 2948-2956 (2001)
101. Rajasekar R, Mathews V, Lakshmi KM et al. Plasmacytoid dendritic cell count on day 28 in HLA-matched related allogeneic peripheral blood stem cell transplant predicts the incidence of acute and chronic GVHD. Biol. Blood Marrow Transplant. 14(3), 344-350 (2008)
102. Arpinati M, Chirumbolo G, Bandini G et al. GVHD affects DC-2 recovery after allogeneic PBSC transplantation. Bone Marrow Transplant. 29(Suppl. 2), 661 (2002)
103. + cells in the bone marrow and peripheral blood of patients with chronic graft-versus-host disease. Transplantation 85(12), 1826-1832 (2008)
104. Przepiorka D, Anderlini P, Saliba R et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 98(6), 1695-1700 (2001)
105. Kalaycioglu ME, Bolwell BJ. Eosinophilia after allogeneic bone marrow transplantation using the busulfan and cyclophosphamide preparative regimen. Bone Marrow Transplant. 14(1), 113-115 (1994)
106. Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am. J. Med. 69(2), 204-217 (1980)
107. Jacobsohn DA, Schechter T, Seshadri R, Thormann K, Duerst R, Kletzel M. Eosinophilia correlates with the presence or development of chronic graft-versus-host disease in children. Transplantation 77(7), 1096-1100 (2004)
108. + T cells in mice conditioned with fractionated lymphoid irradiation protects against graft-versus-host disease: natural suppressor cells. J. Immunol. 167(4), 2087-2096 (2001)
109. Lan F, Zeng D, Higuchi M, Higgins JP, Strober S. Host conditioning with total lymphoid irradiation and anti-thymocyte globulin prevents graft-versus-host disease: the role of CD1-reactive natural killer T cells. Biol. Blood Marrow Transplant. 9(6), 355-363 (2003)
110. + Tregs that protects against graft-versus-host disease. Blood 113(18), 4458-4467 (2009)
111. Kohrt HE, Turnbull BB, Heydari K et al. TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood 114(5), 1099-1109 (2009)
112. Larghero J, Rocha V, Porcher R et al. Association of bone marrow natural killer cell dose with neutrophil recovery and chronic graft-versus-host disease after HLA identical sibling bone marrow transplants. Br. J. Haematol. 138(1), 101-109 (2007)
113. Skert C, Damiani D, Michelutti A et al. Kinetics of Th1/Th2 cytokines and lymphocyte subsets to predict chronic GVHD after allo-SCT: results of a prospective study. Bone Marrow Transplant. 44(11), 729-737 (2009)
114. Imamura M, Tsutsumi Y, Miura Y, Toubai T, Tanaka J. Immune reconstitution and tolerance after allogeneic hematopoietic stem cell transplantation. Hematology 8(1), 19-26 (2003)
115. Ruggeri L, Mancusi A, Burchielli E et al. NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation. Blood Cells Mol. Dis. 40(1), 84-90 (2008)
116. Schultz KR, Paquet J, Bader S, Hayglass KT. Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease. Bone Marrow Transplant. 16(2), 289-295 (1995)
117. Kim SJ, Lee JW, Jung CW et al. Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective multicenter Phase II study. Haematologica 95(11), 1935-1942 (2010)
118. Miklos DB, Kim HT, Zorn E et al. Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood 103(1), 353-359 (2004)
119. Miklos DB, Kim HT, Miller KH et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 105(7), 2973-2978 (2005)
120. Patriarca F, Skert C, Sperotto A et al. The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery. Exp. Hematol. 34(3), 389-396 (2006)
121. Kier P, Penner E, Bakos S et al. Autoantibodies in chronic GVHD: high prevalence of antinucleolar antibodies. Bone Marrow Transplant. 6(2), 93-96 (1990)
122. Wechalekar A, Cranfield T, Sinclair D, Ganzckowski M. Occurrence of autoantibodies in chronic graft vs. host disease after allogeneic stem cell transplantation. Clin. Lab. Haematol. 27(4), 247-249 (2005)
123. Quaranta S, Shulman H, Ahmed A et al. Autoantibodies in human chronic graft-versus-host disease after hematopoietic cell transplantation. Clin. Immunol. 91(1), 106-116 (1999)
124. Moon JH, Lee SJ, Kim JG et al. Clinical significance of autoantibody expression in allogeneic stem-cell recipients. Transplantation 88(2), 242-250 (2009)
125. Fujii H, Cuvelier G, She K et al. Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children s Oncology Group. Blood 111(6), 3276-3285 (2008)
126. Svegliati S, Olivieri A, Campelli N et al. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood 110(1), 237-241 (2007)
127. Zhang J, Roschke V, Baker KP et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J. Immunol. 166(1), 6-10 (2001)
128. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 44(6), 1313-1319 (2001).
129. Groom J, Kalled SL, Cutler AH et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sj gren s syndrome. J. Clin. Invest. 109(1), 59-68 (2002)
130. Thien M, Phan TG, Gardam S et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 20(6), 785-798 (2004)
131. Sarantopoulos S, Stevenson KE, Kim HT et al. High levels of βcell activating factor in patients with active chronic graft-versus-host disease. Clin. Cancer Res. 13(20), 6107-6014 (2007)
132. Sarantopoulos S, Stevenson KE, Kim HT et al. Recovery of βcell homeostasis after rituximab in chronic graft-versus-host disease. Blood 117(7), 2275-2283 (2011)
133. Daridon C, Devauchelle V, Hutin P et al. Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjögren s syndrome. Arthritis Rheum. 56(4), 1134-1144 (2007)
134. Morimoto S, Nakano S, Watanabe T et al. Expression of BAFF in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production. Rheumatology (Oxford) 46(7), 1083-1086 (2007)
135. Thanou-Stavraki A, Sawalha AH. An update on belimumab for the treatment of lupus. Biologics 5, 33-43 (2011)
136. She K, Gilman AL, Asianian S et al. Altered Toll-like receptor 9 responses in circulating B cells at the onset of extensive chronic graft-versus-host disease. Biol. Blood Marrow Transplant. 13(4), 386-397 (2007)
137. D Orsogna LJ, Wright MP, Krueger RG et al. Allogeneic hematopoietic stem cell transplantation recipients have defects of both switched and IgM memory B cells. Biol. Blood Marrow Transplant. 15(7), 795-803 (2009)
138. + B cells identify patients with active chronic graft-versus-host disease. Biol. Blood Marrow Transplant. 14(2), 208-219 (2008)
139. Isnardi I, Ng YS, Menard L et al. Complement receptor 2/CD21-negative human naive B cells mostly contain autoreactive unresponsive clones. Blood 115(24), 5026-5036 (2010)
140. Kuzmina Z, Greinix HT, Weigl R et al. Significant differences in βcell subpopulations characterize patients with chronic graft-versus-host disease associated dysgammaglobulinemia. Blood 117(7), 2265-2274 (2011)
141. Perruche S, Marandin A, Kleinclauss F et al. Association of mixed hematopoietic chimerism with elevated circulating autoantibodies and chronic graft-versus-host disease occurrence. Transplantation 81(4), 573-582 (2006)
142. Cuvelier GD, Kariminia A, Fujii H et al. Anti-CD13 Abs in children with extensive chronic GVHD and their relation to soluble CD13 after allogeneic blood and marrow transplantation from a Children s Oncology Groups Study, ASCT0031. Bone Marrow Transplant. 45(11), 1653-1670 (2010)
143. Larsen SL, Pedersen LO, Buus S, Stryhn A. T cell responses affected by aminopeptidase N (CD13)-mediated trimming of major histocompatibility complex class II-bound peptides. J. Exp. Med. 184(1), 183-189 (1996)
144. Tani K, Ogushi F, Huang L et al. CD13/aminopeptidase N, a novel chemoattractant for T lymphocytes in pulmonary sarcoidosis. Am. J. Respir. Crit. Care Med. 161(5), 1636-1642 (2000)
145. Shimizu T, Tani K, Hase K et al. CD13/aminopeptidase N-induced lymphocyte involvement in inflamed joints of patients with rheumatoid arthritis. Arthritis Rheum. 46(9), 2330-2338 (2002)
146. Kobayashi S, Imamura M, Hashino S, Tanaka J, Asaka M. Clinical relevance of serum soluble interleukin-2 receptor levels in acute and chronic graft-versus-host disease. Leuk. Lymphoma 28(1-2), 159-169 (1997)
147. Liem LM, van Houwelingen HC, Goulmy E. Serum cytokine levels after HLA-identical bone marrow transplantation. Transplantation 66(7), 863-871 (1998)
148. Balon J, Halaburda K, Bieniaszewska M et al. Early complete donor hematopoietic chimerism in peripheral blood indicates the risk of extensive graft-versus-host disease. Bone Marrow Transplant. 35(11), 1083-1088 (2005)
149. Pavletic SZ, Smith LM, Bishop MR et al. Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation. Am. J. Hematol. 78(4), 265-274 (2005)
150. Sohn SK, Kim DH, Baek JH et al. Risk-factor analysis for predicting progressive- or quiescent-type chronic graft-versus-host disease in a patient cohort with a history of acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplant. 37(7), 699-708 (2006)
151. Lee JH, Lee JH, Choi SJ et al. Graft-versus-host disease (GVHD)-specific survival and duration of systemic immunosuppressive treatment in patients who developed chronic GVHD following allogeneic haematopoietic cell transplantation. Br. J. Haematol. 122(4), 673-644 (2003)
152. Izutsu KT, Schubert MM, Truelove EL et al. The predictive value of elevated labial saliva sodium concentration: its relation to labial gland pathology in bone marrow transplant recipients. Hum. Pathol. 14(1), 29-35 (1983)
153. Izutsu KT, Menard TW, Schubert MM et al. Graft versus host disease-related secretory immunoglobulin A deficiency in bone marrow transplant recipients. Findings in labial saliva. Lab. Invest. 52(3), 292-297 (1985)
154. Izutsu KT, Sullivan KM, Schubert MM et al. Disordered salivary immunoglobulin secretion and sodium transport in human chronic graft-versus-host disease. Transplantation 35(5), 441-446 (1983)
155. Boutin M, Ahmad I, Jauhiainen M et al. NanoLC-MS/MS analyses of urinary desmosine, hydroxylysylpyridinoline and lysylpyridinoline as biomarkers for chronic graft-versus-host disease. Anal. Chem. 81(22), 9454-9461 (2009).